ANK2 Gene Long QT Syndrome Type 4 NGS Genetic DNA Test
Comprehensive Introduction to ANK2 Genetic Testing
The ANK2 Gene Long QT Syndrome Type 4 NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying inherited cardiac rhythm disorders. Long QT Syndrome (LQTS) is a serious heart condition characterized by prolonged QT intervals on electrocardiograms, which can lead to dangerous arrhythmias and sudden cardiac death. Type 4 LQTS, specifically associated with mutations in the ANK2 gene, affects the heart’s electrical signaling system and requires specialized genetic analysis for accurate diagnosis and management.
What This Advanced Test Detects
This comprehensive genetic examination specifically targets the ANK2 gene, which encodes ankyrin-B protein crucial for maintaining proper ion channel function in cardiac cells. The test utilizes Next-Generation Sequencing (NGS) technology to identify:
- Pathogenic mutations in the ANK2 gene associated with Long QT Syndrome Type 4
- Genetic variants affecting cardiac sodium and calcium channel regulation
- Inherited abnormalities in cardiac repolarization mechanisms
- Specific ANK2 gene alterations linked to increased arrhythmia risk
Clinical Indications and Who Should Consider Testing
This genetic test is recommended for individuals experiencing:
- Unexplained fainting episodes or syncope
- Family history of sudden cardiac death or Long QT Syndrome
- Abnormal ECG findings showing prolonged QT intervals
- Recurrent palpitations or arrhythmias without clear cause
- Previous cardiac events during physical exertion or emotional stress
- Family members of individuals with confirmed ANK2 mutations
Significant Benefits of ANK2 Genetic Testing
Undergoing this specialized genetic analysis provides numerous advantages:
- Early Risk Identification: Detect genetic predisposition before symptoms manifest
- Personalized Treatment Planning: Tailor medication and lifestyle recommendations
- Family Screening Guidance: Identify at-risk relatives for preventive care
- Definitive Diagnosis: Confirm Long QT Syndrome Type 4 with genetic evidence
- Proactive Management: Implement preventive measures to reduce cardiac event risk
- Reproductive Planning: Understand inheritance patterns for family planning
Understanding Your Test Results
Your genetic test results will be carefully interpreted by our expert genetic counselors and cardiologists:
- Positive Result: Indicates presence of ANK2 mutation associated with Long QT Syndrome Type 4, requiring comprehensive cardiac evaluation and management
- Negative Result: Suggests absence of tested ANK2 mutations, though clinical monitoring may still be recommended based on symptoms
- Variant of Uncertain Significance: Identifies genetic changes with unknown clinical impact, requiring ongoing research and periodic re-evaluation
All results include detailed consultation with our cardiac genetics specialists to ensure complete understanding and appropriate next steps.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| ANK2 Gene Long QT Syndrome Type 4 NGS Genetic DNA Test | $500 USD | $700 USD |
Nationwide Accessibility
We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and numerous other cities. Our comprehensive network ensures accessible cardiac genetic testing for patients nationwide.
Take Control of Your Cardiac Health Today
Don’t wait to understand your genetic risk for Long QT Syndrome Type 4. Our specialized ANK2 genetic testing provides the clarity needed for informed cardiac health decisions. With results available in 3-4 weeks and simple sample collection (blood, extracted DNA, or blood spot on FTA card), getting tested has never been more convenient.
Call or WhatsApp our cardiac genetics specialists today at +1(267) 388-9828 to schedule your comprehensive ANK2 genetic evaluation and take the first step toward personalized cardiac care management.

